Giovanni M. Bariani
Sao Paulo, SP, Brazil
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
Pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient advanced solid tumors: updated results of the KEYNOTE-158 trial.
Journal: Nature cancer
Published: August 03, 2023
Health-related quality of life with pembrolizumab monotherapy in patients with previously treated advanced microsatellite instability high/mismatch repair deficient endometrial cancer in the KEYNOTE-158 study.
Journal: Gynecologic oncology
Published: March 29, 2022
Health-related quality of life in patients treated with pembrolizumab for microsatellite instability-high/mismatch repair-deficient advanced solid tumours: Results from the KEYNOTE-158 study.
Journal: European journal of cancer (Oxford, England : 1990)
Published: March 25, 2022
Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 06, 2022
Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: December 14, 2021
Spotlight on International Quality: COVID-19 and Its Impact on Quality Improvement in Cancer Care.
Journal: JCO global oncology
Published: October 29, 2021
Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study.
Journal: The lancet. Gastroenterology & hepatology
Published: July 20, 2021
Hepatoid esophagogastric adenocarcinoma and tumoral heterogeneity: a case report.
Journal: Journal of gastrointestinal oncology
Published: May 20, 2021
A Prospective Cohort Study of Biomarkers in Squamous Cell Carcinoma of the Anal Canal (SCCAC) and their Influence on Treatment Outcomes.
Journal: Journal of Cancer
Published: December 29, 2020
Regorafenib in Patients with Antiangiogenic-Naïve and Chemotherapy-Refractory Advanced Colorectal Cancer: Results from a Phase IIb Trial.
Journal: The oncologist
Published: January 24, 2019
Evaluation of 18F-FDG PET-CT as a prognostic marker in advanced biliary tract cancer.
Journal: Nuclear medicine communications
Published: January 31, 2018
Phase II Study of Capecitabine in Substitution of 5-FU in the Chemoradiotherapy Regimen for Patients with Localized Squamous Cell Carcinoma of the Anal Canal.
Journal: Journal of gastrointestinal cancer
Published: December 23, 2015
Last Updated: 09/26/2026